- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innoviva Inc (INVA)
NASDAQ
Symbol | Exchange | Currency |
|---|
14.56
-0.18(-1.22%)
After Hours
14.56
0.00(0.00%)
- Real-time Data
- Volume:399,897
- Day's Range:14.50 - 14.70
- 52 wk Range:13.64 - 20.71
INVA Overview
- Prev. Close
- 14.74
- Day's Range
- 14.5-14.7
- Revenue
- 403.82M
- Open
- 14.65
- 52 wk Range
- 13.64-20.71
- EPS
- 1.43
- Volume
- 399,897
- Market Cap
- 1.01B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 847,130
- P/E Ratio
- 11.77
- Beta
- 0.455
- 1-Year Change
- -11.17%
- Shares Outstanding
- 69,705,967
- Next Earnings Date
- Nov 02, 2022
What is your sentiment on Innoviva?
or
Market is currently closed. Voting is open during market hours.
Innoviva Inc News
- Innoviva Misses Q2 EPS
- ByInvesting.com-
Innoviva (INVA) reported Q2 EPS of $0.05, which may not compare to the analyst estimate of $0.44. Revenue for the quarter came in at $111.7 million versus the consensus estimate of...
- Pre-Open Movers: Twitter Sinks, DWAC Gains as Musk Walks Away from Deal
- ByInvesting.com-
Pre-Open Stock Movers:La Jolla Pharmaceutical Co (NASDAQ:LJPC) 81% HIGHER; Innoviva Inc (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing...
Innoviva Inc Analysis
- 5 Stocks To Grab As Gold Prices Surge On Coronavirus Fears
With coronavirus on the verge of becoming a global pandemic, investors went into overdrive scurrying for safe-haven assets to counter the uncertainty. This, in turn, sent gold...
- What's In Store For Innoviva (INVA) This Earnings Season?
We expect royalties from Innoviva, Inc.’s (NASDAQ:INVA) collaborated drugs to have driven revenues in fourth-quarter 2019.Shares of the company have lost 12.4% in the past...
- Jazz Enrolls First Patient In Phase II/III Leukemia Study
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that it has enrolled the first patient in the pivotal phase II/III study evaluating its novel asparaginase JZP-458 as a potential...
Innoviva Inc Company Profile
Innoviva Inc Company Profile
Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Neutral | Sell |
| Technical Indicators | Buy | Sell | Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Neutral | Buy | Buy | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 9.40 | 9.42 | 8.98 | +0.250 | +2.73% | 76.05K | NYSE | |||
| 122.88 | 123.26 | 121.57 | +0.23 | +0.19% | 14.59M | NASDAQ | |||
| 49.75 | 50.06 | 49.38 | -0.36 | -0.72% | 15.75M | NYSE | |||
| 101.01 | 101.85 | 99.80 | +0.18 | +0.18% | 61.22M | NASDAQ | |||
| 32.69 | 32.72 | 32.26 | +0.19 | +0.58% | 1.89M | NYSE | |||
| 136.06 | 136.26 | 134.19 | +1.15 | +0.85% | 708.60K | NYSE | |||
| 166.09 | 166.75 | 165.13 | +0.79 | +0.48% | 8.97M | NYSE | |||
| 134.93 | 135.19 | 132.24 | +0.92 | +0.69% | 2.78M | NYSE | |||
| 16.00 | 17.05 | 13.37 | +3.05 | +23.55% | 162.04M | NASDAQ | |||
| 35.76 | 36.03 | 35.03 | -1.38 | -3.72% | 7.63M | NYSE | |||
| 94.18 | 94.61 | 92.38 | -0.59 | -0.62% | 11.47M | NYSE | |||
| 15.25 | 15.25 | 15.10 | +0.10 | +0.66% | 2.71K | NASDAQ | |||
| 438.01 | 439.97 | 429.86 | +3.77 | +0.87% | 884.84K | NYSE | |||
| 249.11 | 251.99 | 247.51 | -0.19 | -0.08% | 6.50M | NASDAQ | |||
| 11.28 | 11.28 | 11.27 | -0.07 | -0.62% | 56.00 | NASDAQ |
- Jul 09, 2021, 22:14strong undervalued stock